Home/Filings/4/0001415889-24-004167
4//SEC Filing

CR Group L.P. 4

Accession 0001415889-24-004167

CIK 0001492674other

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 5:17 PM ET

Size

19.2 KB

Accession

0001415889-24-004167

Insider Transaction Report

Form 4
Period: 2024-02-14
Transactions
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
Transactions
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
Transactions
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
Transactions
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
Transactions
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
Transactions
  • Conversion

    Common Stock

    2024-02-14+335,947335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
  • Conversion

    Series B Preferred Stock

    2024-02-1433,594.710 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)
    From: 2023-07-03Common Stock (335,947 underlying)
  • Conversion

    Common Stock

    2024-02-14+488,273488,273 total(indirect: By: CRG Partners III Parallel Fund B LP)
  • Conversion

    Series B Preferred Stock

    2024-02-1448,827.310,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)
    From: 2023-07-03Common Stock (488,273 underlying)
Footnotes (3)
  • [F1]Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration.
  • [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
  • [F3]The preferred stock has no expiration date.

Issuer

T2 Biosystems, Inc.

CIK 0001492674

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001702352

Filing Metadata

Form type
4
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 5:17 PM ET
Size
19.2 KB